{Reference Type}: Journal Article
{Title}: Cardiac Myosin Activation in the Treatment of Congestive Heart Failure: New Therapeutic Options and Review of Literature.
{Author}: Ali A;Abdelmaseih R;Thakker R;Faluk M;Hasan SM;Ali A;Abdelmaseih R;Thakker R;Faluk M;Hasan SM;Ali A;Abdelmaseih R;Thakker R;Faluk M;Hasan SM;
{Journal}: Heart Views
{Volume}: 22
{Issue}: 4
{Year}: Oct-Dec 2021
暂无{DOI}: 10.4103/HEARTVIEWS.HEARTVIEWS_39_21
{Abstract}: Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.